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Background: Resistin is a circulating adipokine with insulin-antagonizing effects. The aim of this study was to investigate
the relationship between the single nucleotide polymorphism (SNP) -420C > G in the resistin gene with serum resistin
levels, insulin resistance, and risk of gestational diabetes (GDM) in Iranian population.
Method: 75 GDM patients and 70 healthy pregnant women were enrolled in this study. Genotyping for SNP- 420C > G
in the resistin gene was performed by the polymerase chain reaction- restriction fragment length polymorphism
(PCR-RFLP) method. Serum resistin and insulin were measured by immunoassay. Blood glucose levels and lipid
profile were measured by enzymatic methods. Homeostasis model of assessment for insulin resistance (HOMA-IR)
were calculated.
Result: GG genotype and G allele of SNP-420C > G were more frequent in GDM patients compared to non-GDM
subjects. Serum resistin level was similar in GDM and non-GDM patients. The serum levels of resistin in GDM and
non-GDM women with GG genotype were similar to those with GC + CC genotype. Multivariate logistic regression
analysis after adjusting for confounding factors showed a higher susceptibility to GDM in patients with GG genotype
compared to subjects with GG + GT genotype (odds ratio = 4.59, 95% CI; 1.96-10.71, p = 0.00). Serum resistin level was
correlated with serum triglyceride, total and low density lipoprotein (LDL) cholesterol (p < 0.05) in GDM patients. No
significant association was found between serum resistin, insulin resistance, and SNP-420C > G.
Conclusion: The SNP-420C/G of resistin gene is associated with genetic susceptibility to GDM in our population.
Further studies are necessary to confirm the role of this polymorphism in pathogenesis of GDM and to explore
potential mechanisms by which it modulates susceptibility to GDM.
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Gestational diabetes mellitus (GDM) is a type of glucose
intolerance that occurs during pregnancy [1]. GDM and
type 2 diabetes (T2D) are closely related disorders with
a common pathogenesis [2]. Ethnicity, family history,
dietary habit, physical inactivity and obesity are among
risk factors implicated in susceptibility to both T2D and
GDM [2,3]. Insulin resistance is an important character-
istic of both T2D and GDM [2]. Several adipokines
including leptin, visfatin, adiponectin and resistin are* Correspondence: takhshid2001@yahoo.co.uk
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unless otherwise stated.reported to be involved in development of insulin resist-
ance [4,5].
Resistin is a cysteine-rich polypeptide with 108 amino
acid residues synthesized and secreted by adiopcytes,
immune and endothelial cells [6]. In pregnancy, the pla-
centa is a major source of maternal circulating resistin
[7]. Initial studies in rodent animal models suggested
that resistin involves in insulin resistance and T2D.
Indeed, up-regulation of resistin in obese animal rodent
models, decrease in its circulating level by thiazolidine-
diones (TZDs), and decrease in plasma glucose level in
response to anti-resistin antibody administration in
obese animals have been reported [8]. However, the
exact role of resistin in the pathogenesis of insulinentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the association between elevated circulating resistin and
insulin resistance has been suggested in some studies
[9,10], other studies fail to detect such an association
[11,12]. Several inconsistent findings have also been re-
ported from serum resistin levels in patients with GDM.
Most of these findings showed no difference in the
serum resistin level between GDM and normal glucose
tolerant (NGT) subjects [13,14]. However, there are
other reports indicating increased [15,16] or decreased
[7] serum resistin concentrations in women with GDM
compared with NGT pregnant women.
The gene encoded resistin (RETN gene) is located
on 19p3.2 and composed of four exons and three in-
trons. It is a polymorphic gene with several single
nucleotide polymorphism (SNPs) in its promoter, in-
trons and 3′-UTR (3′-untranslated region) regions [17].
Because of its possible influence on RETN gene ex-
pression and circulating resistin concentration, SNP-
420C > G (rs 1862513) in the promoter is one of the
most studied SNPs of RETN gene [17-20]. It has been
reported that the promoter activity of RETN is higher
in individuals with GG genotype of SNP-420C > G
compared to CC/GC genotype [19]. The association of
SNP-420C > G genotype with T2D has been shown in
some previous studies [19,21]. Because of the close re-
lationship between T2D and GDM, it is reasonable to
evaluate the association between this SNP and susceptibil-
ity to GDM. Thus, the first aim of our study was to evalu-
ate the association of SNP- 420C >G with risk of GDM in
Iranian population. We also aimed to compare serum
resistin level between GDM and non-GDM subjects, as
well as its association with genotypes of SNP-420C >G.
Furthermore, we examined possible associations between
serum resistin levels with obesity, insulin resistance and
serum biochemical abnormalities related to GDM.
Material
All subjects enrolled in the present study were Iranian
and recruited from outpatient clinic of Hafez and
Zinabieh Hospitals in Shiraz, Iran, between September
2011 and May 2013. The subjects were firstly screened
for presence of GDM, using 50-g glucose challenge
test (GCT) at 24-28th weeks of gestation. For the
pregnant women with positive results of GCT (plasma
glucose ≥140 mg/dl), 100-g three hour oral glucose toler-
ance test (3 hrs - OGTT) was performed and the subjects
with at least two results higher than normal values
(fasting < 95 mg/dl, 1 h <180 mg/dl, 2 h <155 mg/dl
and 3 < 140 mg/dl ) were diagnosed as GDM [22]. Sev-
enty healthy pregnant women and seventy five pregnant
women who had GDM were enrolled in this study. The
absence of family history for the T2D, absence of clinical
evidence of any major disease and absence of medicationuse that may alter glucose tolerance were the inclusion
criteria for the control pregnant women. The inclusion
criteria for the pregnant women with GDM were:
(1) newly diagnosed cases, and (2) no previous use of oral
hypoglycemic agents. The exclusion criteria from the
study were the presence of type-1 or type-2 diabetes
mellitus and other known major diseases. Maternal BMI
(kg/m2) was calculated as the ratio of the weight (kg) to
the square of the height (m). The study protocol was
approved by the ethics committee at Shiraz university of
Medical Sciences, Shiraz, Iran. Informed written consent
was obtained from all participants.
Biochemical determinations
Fasting venous maternal blood sample was collected
in both groups, after an overnight 12 hour fasting.
Sera were separated immediately and stored at −70 C
until biochemical analyses were performed. Fasting
plasma glucose (FPG), total cholesterol (TC), trigly-
ceride (TG) and high-density lipoprotein cholesterol
(HDL-C) were measured by using commercially avail-
able kits. Fasting plasma low-density lipoprotein
cholesterol (LDL C) was calculated using the formula
of Friedewald et al. [23]; LDL-C = total cholesterol
(TC) – (HDL-C) - [triglycerides (TG) ÷ 5]. HbA1C was
measured by ion-exchange high performance liquid chro-
matography. Serum insulin levels were measured by
radioimmunoassay using available commercial kits. Serum
resistin concentration was measured by immunoassay
using a commercially human resistin ELISA kit (Biovendor,
Czech Republic) according to the manufacturer’s in-
structions. The lowest detectable level of serum resistin
was 0.012 ng/ml and intra- and inter-assay coefficients
of variation of the assay were 5.9% and 7.6%, respect-
ively. In this study, HOMA-IR (homeostasis model of
assessment for insulin resistance) was used for evalu-
ation of insulin sensitivity. HOMA-IR is defined as follows:
([fasting glucose] × [fasting insulin])/22.5 [24].
RETEN gene SNP −420 C/G genotyping
Genomic DNA was extracted from EDTA treated whole
blood using DNP™ kit (Cinnagen, Iran). The extracted
genomic DNA was stored at −70 C prior to polymerase
chain reaction (PCR). Genotyping for detection of
SNP −420 C/G of the RETEN gene was performed
using PCR-RFLP (restriction fragment length poly-
morphisms) method. In brief, a DNA fragment con-
taining the SNP −420 C/G was amplified by 5′TGT
CATTCTCACCCAGAGACA-3′ as the forward primer
and 5′GGGCTCAGCTAACCAAATC-3′ as the reverse
primer [25]. PCR thermal cycling was started with initial
denaturation at 95°C for 5 min, followed with 35 cycles
of amplification which included denaturation at 95°C for
30 sec, annealing at 60°C for 30 sec, extension at 72°C for
Table 1 Demographic characteristics and biochemical







Age(y) 29.4 ± 4.9 26.7 ± 5.0 0.73
Takhshid and Zare Journal of Diabetes & Metabolic Disorders  (2015) 14:37 Page 3 of 730 sec, and final extension at 72°C for 10 min. PCR
products were digested by Bbs I restriction enzyme
(Fermentas Life Sciences, Lithuania) and separated
on 2% agarose gel electrophoresis. The GG homozygous
genotype was marked by a single 534 bp (undigested)
fragment. PCR products were cleaved into two fragments
of 327 and 207 bp in the presence of CC homozy-
gous genotype and three fragments of 534,327 and
207 bp for GC heterozygous genotype (Figure 1). In
order to evaluate the reproducibility of the genotyp-
ing procedure, duplicate genotyping reactions were
performed for 10% of the samples. Genotyping success
rate was >98%.
Statistical methods
All statistical analyses were performed using SPSS 15.0
software (SPSS Inc., Chicago, IL, USA). The normality of
distribution of the continuous variables in groups was
assessed by the Shapiro–Wilk test. The normally distrib-
uted variables were analyzed applying the Student’s
t-test, and the variables that did not show a normal
distribution were compared using Mann–Whitney U-test.
The data were presented in mean ± standard devi-
ation (SD) or ratio and percent. Bivariate correlation
(computing Pearson’s coefficient with their significance
levels) between maternal serum resistin levels and mater-
nal blood insulin, FPG, HOMA-IR, BMI, gestational age,
maternal age in the GDM and non-GDM subjects was
calculated. Multiple linear regression analysis was con-
ducted using the stepwise method to determine which
factors were significantly and independently associated
with maternal serum resistin. The differences in serum
resistin levels between GDM and Non- GDM subjects
were analyzed using ANCOVA after adjustment for
covariates (maternal age, gestational age, BMI, and
HOMA-ir).The Chi-square test was used to compare
frequencies of allele and genotypes. To examine theFigure 1 Genotypes of −420 C > G polymorphism of resistin gene
determined by PCR-RFLP method and analyzed by a 2% agarose gel
electrophoresis stained with ethidium bromide and viewed under
UV light. The size of the restriction fragments is shown.independent association of the SNP -420C > G with
GDM, univariate and multivariate logistic regression
analysis was conducted. In the regression models,
GDM status was chosen as the dependent variable
and GG and GC + CC genotypes as the independent
variable. Confounding variables including maternal
BMI, maternal age, and maternal HOMA-index were
later included in the model. For all comparisons, the
statistical significance was defined by a P < 0.05.
Results
Comparison of baseline characteristics between subjects
with and without GDM
The baseline demographic and clinical characteristics
of patients with GDM and non-GDM controls are
shown in Table 1. As can be seen in Table 1, maternal
age, gestational age and BMI of the subjects were
similar in the groups. GDM patients had a signifi-
cantly higher insulin resistance index (as assessed by
HOMA-IR) (P < 0.01), fasting blood glucose (P < 0.01)
and HbA1C (P < 0.001) than non-GDM subjects. Blood
lipid levels were similar in the groups. The mean of serum
resistin levels was similar in GDM group (13.3 ± 7.4,
ranging from 1.1 to 28.0 ng/ml) and non-GDM sub-
jects (11.4 ± 6.9, ranging from 1.3 to 26.7 ng/ml)
(Table 1). Adjustment for maternal age, gestational age,
BMI category (normal weight; BMI < 25 and overweight/
obesity; BMI ≥ 25 ), and HOMA-IR did not significantly
change the results.Gestational age(week) 29.9 ± 3.4 29.6 ± 3.1 0.60
BMI(Kg/m2) 28.2 ± 4.5 28.1 ± 4.4 0.94
FPG(mg/dl) 87.9 ± 22.4 78.7 ± 11.3 0.002*
HbA1C (%) 5.80 ± 0.95 5.08 ± 0.37 < 0.001*
Insulin(μIU/ml) 18.2 ± 11.6 17.5 ± 7.4 0.67
HOMA-IR 4.6 ± 3.1 3.4 ± 1.6 0.005*
TG(mg/dl) 267.3 ± 121.2 267.8 ± 101.9 0.98
TC(mg/dl ) 230.7 ± 50.9 240.0 ± 51.1 0.27
HDL-C(mg/dl ) 52.4 ± 13.6 52.6 ± 12.4 0.55
LDL-C(mg/dl ) 113.6 ± 28.7 118.7 ± 27.6 0.28
Resistin (ng/ml) 13.0 ± 6.6 11.4 ± 6.9 0.36
GDM: gestational diabetes mellitus, BMI: body mass index. FPG: fasting
plasma glucose. HbA1c: hemoglobin A1c. HDL-C: high-density lipoprotein
cholesterol. LDL-C: low-density lipoprotein cholesterol. HOMA-IR: homeostasis
model assessment index for insulin resistance. Values are presented as
mean ± SD. Student- t test was used for comparing the data between
groups. *Statistically significant.
Table 2 Genotype and allele frequencies of RETN gene SNP −420 C/G in the non – GDM (control) and GDM patients
Genotype frequency Allele frequency
Group n GG GC + CC p G C p
Non-GDM 67 11(16.4%) 56(83.6%) 0.025* 69(51.5%) 65(49.5%) 0.045*
GDM 75 33(44%) 42(56%) 108(72%) 42(28%)
OR (95% CI), 4.0 (1. 8–8.8) OR (95% CI), 2.4 (1.48 -3.96)
Genotypes are reported as number with percent in parentheses. *Two-tailed chi-square test (χ2). 95% CI = 95% confidence interval.
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Serum resistin concentration did not show any signifi-
cant correlation with GDM related risk factors including
maternal age(r = 0.053; p = 522), BMI(r = 0.051; p < 0.538),
and HOMA-IR(r = 0.006; p < 0.946), in entire cohort.
Pearson correlation analysis showed that fasting serum
resistin concentrations were positively correlated with
TG (r = 0.293; p < 0.03), TC(r = 0.288; p = 0.032), LDL-C
(r = 0.353; p = 0.011) in GDM patients. Stepwise linear
regression analysis revealed that TG (β = 0.353, P = 0.002)
was the independent predictor of serum resistin and
accounted for 12.5% of the variance.
Genotype and allele analysis of SNP -420C > G
The genotype and allele frequencies in our case–control
samples are shown in Table 2. The results showed
that the frequency of GG genotype (p = 0.025, odds
ratio = 2.62, 95% CI; 1.08-6.36) and G allele (p = 0.045,
odds ratio = 2.14, 95% CI 0.97-4.73) were higher in the
GDM patients compared to the non-GDM group (Table 2).
Logistic regression analysis was performed to test the
association of SNP -420C > G with GDM. The findings
of this analysis showed that the frequency of GG geno-
type of SNP -420C > G was 3.9-fold higher in GDM
women than non-GDM women (odds ratio = 3.9,
95% CI; 1.77-8.56, p = 0.001). To examine the inde-
pendent association of genotype with susceptibility to
GDM, multivariate logistic regression analysis with
confounding factors including age, BMI and HOMA-
index of mothers, was then conducted. The results
(Table 3) showed that after adjusting for covariates,
the frequency of GG genotype of SNP -420C > G was
still higher in GDM women than non-GDM womenTable 3 Multivariate logistic regression analysis for
gestational diabetes
Variables B SE Wald P OR 95.0% C.I
Age 0.13 0.04 9.27 0.001 1.138 1.05-1.23
SNP - 420 C/G 1.52 0.46 12.41 0.000 4.59 1.96-10.71
HOMA-IR 0.18 0.11 2.62 0.156 1.177 0.94-1.47
BMI 0.03 0.07 0.01 0.642 1.031 0.91-1.17
Logistic regression analysis was performed for SNP - 420 C/G with adjustment
for confounding factors (age, BMI, and HOMA-IR). BMI: body mass index,
HOMA-IR: homeostasis model assessment index for insulin resistance. OR; odds
ratios, CI; confidence intervals.(odds ratio = 4.59, 95% CI; 1.96-10.71, p = 0.00). There
were no significant differences between genotypes of
SNP - 420C > G with respect to BMI and circulating
concentrations of serum resistin (Table 4).
Discussion
The findings of this study showed that GG genotype
and G- allele of SNP- 420C/G in the RETN gene is
associated with genetic susceptibility to GDM in our
population. The second finding of this study was the
positive correlation between the serum concentration
of atherogenic lipids and serum resistin. However, no
significant associations were observed between serum
resistin levels, SNP- 420C/G in the patients with
GDM.
Allelic and genotypic frequencies of SNP- 420C/G
(rs1862513) show ethnic variation [21]. In this study, the
frequency of rare G/G genotypes and G allele among the
control NGT women was 16.4% and 51.5%, respectively.
This is closely comparable with another Iranian data by
Emamogolipour, et al. [26] but higher than those
reported for healthy Caucasian, Chinese, Korean and
Japanese subject (24% to 30%) [18,27,28]. Previous stud-
ies have shown an association between G allele of SNP-
420C/G and T2D in Iranian and other population
[19,26]. To best of our knowledge, this is the first study
that revealed the association of SNP- 420C/G with
GDM. Our data showed that the frequency of GG geno-
type and G allele was significantly higher in the GDM
patients compared to normal pregnant group. The exact
molecular mechanisms that link this polymorphism with
GDM are not known at present. It has been previously
reported that G allele of SNP- 420 in the promoter of
RETN gene was associated with increase in circulating
resistin [18,19]. According to the authors, this could be
related to specific recognition of – 420G by Sp 1/3,
which increases RETN promoter activity, leading to en-
hanced serum resistin levels. In this study, we did not
observe any association between serum resistin levels
and SNP- 420G. It has been reported that resistin gene
expression is controlled by genetics and environmental
factors such as dietary habits [29,30]. Indeed, an ethnic
specific resistin gene expression has been suggested [31].
Onum et al. [32] suggested that this ethnic difference
may be related to SNP-385 in the RETN gene. They
Table 4 Variations in serum resistin concentration (ng/ml) and BMI (kg/mg2) by genotypes of the SNP −420 C/G
Variable GDM patients genotype Non-GDM subjects genotype
GG GC + CC P value GG GC + CC P value
Resistin (ng/ml) 13.8 ± 5.3 12.5 ± 7.2 0.41 13.7 ± 2.9 11.9 ± 7.7 0.43
(11.7- 15.9) (10.3 - 14.7) (11.8- 15.5) (9.8 - 13.9)
BMI(Kg/m2) 28.2 ± 5.3 28.2 ± 3.3 0.95 28.2 ± 4.4 27.9 ± 4.1 0.84
(26.6 – 29.9) (27.0 – 29.4) (27.0 – 29.3) (25.3 – 30.6)
Values are mean ± SD (95% confidence interval). ANOVA and least significant difference (LSD) as post hoc tests was used to compare the means of circulating
resistin and BMI between different genotype of SNP -420C/G. BMI: body mass index.
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the G allele of SNP-420 in subjects with G-A haplotype
conferred the highest circulating resistin concentration.
On the basis of onum et al.’s hypothesis, the ethnic dif-
ferences in SNP- 358 might account for the discrep-
ancy observed in association of SNP- 420 with serum
resistin in different population [32]. We did not
evaluate SNP-358 in this study; hence, it is not clear
whether the A of SNP- 358 indeed accounts for of
any association between plasma rsistin and SPN-420
in our population.
In agreement with the results of two previous studies
[33,34], our findings showed that serum resistin levels
were similar in the GDM and non- GDM subjects. By
contrast, other studies have found lower [7] or higher
[15,16] resistin levels in GDM patients compared to
healthy pregnant women. These discrepancies mostly
arise from the presence of heterogeneities in the several
aspects of aforementioned studies. One of the causes of
these heterogeneities among studies is the application
of different GDM diagnostic methods, i.e., National
Diabetes Data Group (NDDG, 100 g 3 hrs OGTT),
Carpenter and Coustan (100 g 3 hrs OGTT), and WHO
criteria (75 g 2 hrs OGTT) [35]. Since these methods
had different criteria for diagnosis of GDM, the popula-
tion of GDM patients as well as control subjects that
enrolled in the aforementioned studies substantially dif-
ferent in aspect of level of hyperglycemia and severity of
GDM. Moreover, it has been reported that the maternal
serum resisin is increased in concomitant with the in-
crease in the gestational age [36]. Therefore, difference
in the gestational age of the subjects at the time blood
sampling for resistin assay is the second cause of hetero-
geneity between these studies. The discrepancies be-
tween the studies may also be a reflection of genetic and
anthropometric variations among ethnic groups that en-
rolled in these studies, as some functional polymorphism
in the resistin gene as well as obesity has been showed
that influenced on the expression of resistin in some
ethnic group. Finally, difference in preparation of sample
(serum/plasma), conditions of sample storage, and assay
methods which used for the quantification of resistin
may also consider as a plausible explanation fordifference among studies, as variable results has been
reported for the concentration circulating resistin in
these studies [35].
Resistin has been reported to be related to obesity and
insulin in patients with T2D [20,37]. Similar to T2D in-
sulin resistance and obesity are involved in the etiology
of GDM [2]. Increases in HOMA-ir and serum insulin
concentration are the representative parameter of insulin
resistance [38]. Consistent with other studies, the results
of the present study revealed that HOMA- ir was signifi-
cantly higher in GDM patients compared to healthy
pregnant women. However, serum resistin levels in
GDM group did not show any correlation with HOMA-ir,
serum insulin concentration. These results are in line with
other studies [13,34], suggesting that serum resistin levels
may not be associated with insulin resistance in GMD
patients.
The increase in serum TG, total cholesterol, LDL chol-
esterol concentration and high TG/HDL-C ratio are
atherogenic markers that correlate with insulin resist-
ance [39]. Similar to other studies [30,40], a strong posi-
tive correlation was found among serum resistin, serum
TG, total cholesterol, LDL cholesterol concentration,
and TG/ HDL ratio in the present study. Our results
also demonstrated that the serum levels of atherogenic
lipids were elevated in GDM patients with the highest
quartile resistin, which suggested that increase in resistin
concentration might be closely associated with modula-
tion of lipid metabolism and may play a role in dyslipid-
emia in GDM patients.
Several SNPs were known in the RETN gene but we
considered only the SNP-420C > G in the promoter of
gene because of its possible influence on RETN gene
expression and circulating resistin concentration. Hence,
further studies will be required to clarify the association
among resistin gene polymorphisms, circulating resistin
and GDM.
Conclusion
In conclusion, the findings of the present study suggest
that GG genotype of SNP- 420C/G in the promoter
of RETN associated with genetic susceptibility to GDM
in our population. However, we failed to show any
Takhshid and Zare Journal of Diabetes & Metabolic Disorders  (2015) 14:37 Page 6 of 7association between this polymorphism and known risk
factors of GDM. Thus, further studies are necessary to
confirm the role of this polymorphism in the pathogen-
esis of GDM and to explore the potential mechanisms
by which it modulates susceptibility to GDM.
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